1. Cell Cycle/DNA Damage Cytoskeleton Apoptosis
  2. Microtubule/Tubulin Apoptosis Bcl-2 Family Caspase
  3. CHNQD-01522

CHNQD-01522 是一种靶向 β-微管蛋白 (β-tubulin) 上秋水仙素结合位点的微管 (microtubule) 抑制剂。CHNQD-01522 可结合 β-微管蛋白上的秋水仙素结合位点,抑制微管聚合,并可躲避癌细胞中 P-糖蛋白的转运。CHNQD-01522 可抑制癌细胞增殖、抑制肿瘤细胞集落形成、将细胞周期阻滞于 G2/M 期,并诱导癌细胞凋亡 (apoptosis)。CHNQD-01522 上调 Bax、激活 caspase-9caspase-3。CHNQD-01522 在皮下和原位肝细胞癌异种移植瘤模型中表现出抗肿瘤活性。CHNQD-01522 可用于肝细胞癌的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

CHNQD-01522

CHNQD-01522 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

CHNQD-01522 is a microtubule inhibitor targeting the colchicine binding site on β-tubulin. CHNQD-01522 binds to the colchicine binding site on β-tubulin, inhibits microtubule polymerization, and evades P-glycoprotein transport in cancer cells. CHNQD-01522 inhibits proliferation, suppresses tumor cell colony formation, arrests cell cycle in G2/M phases, and induces apoptosis in cancer cells. CHNQD-01522 upregulates of Bax and activation of caspase-9 and caspase-3. CHNQD-01522 shows anti-tumor efficacy in subcutaneous and orthotopic hepatocellular carcinoma xenograft tumor models. CHNQD-01522 can be used for the research of hepatocellular carcinoma[1].

IC50 & Target[1]

Bax

 

Caspase 3

 

Caspase-9

 

体外研究
(In Vitro)

CHNQD-01522 (Compound 18) (72 h) 可强效抑制 Huh-7、Hep G2、A549、HT-29、U251 和 BT-549 细胞的增殖,IC50 值为 0.17-0.3 μM,且相较于正常 L-02 肝细胞,对癌细胞表现出良好的选择性[1]
CHNQD-01522 (0.125-0.25 μM; 5 days) 可剂量依赖性地抑制 Huh-7 细胞的集落形成,在 0.25 μM 作用 5 天时抑制作用接近完全[1]
CHNQD-01522 (0.125-0.25 μM; 24 h) 可诱导 Huh-7 细胞发生 G2/M 期细胞周期阻滞,24 h 后 0.25 μM 浓度下的 G2/M 期细胞占比显著升高[1]
CHNQD-01522 (0.125-0.25 μM; 24 h) 可在 Huh-7 细胞中诱导显著的细胞凋亡,24 h 后 0.25 μM 浓度下总凋亡细胞数量显著增加[1]
CHNQD-01522 (0.125-0.5 μM; 24 h) 可通过呈剂量依赖性上调 Bax、激活 caspase-9 和 caspase-3,在处理 24 h 后激活 Huh-7 细胞中的线粒体内在凋亡通路[1]
CHNQD-01522 (18) (10-20 μM; 90 min) 可剂量依赖性地抑制微管蛋白聚合,作为一种微管去稳定剂发挥作用[1]
CHNQD-01522 (0.125-0.25 μM; 6 h) 可在 0.125 μM 和 0.25 μM 浓度下处理 Huh-7 细胞 6 h 后破坏其微管细胞骨架的结构[1]
CHNQD-01522 (10-100 μM; 1 h) 可与 Huh-7 细胞裂解物中的 β-tubulin 直接相互作用,提升其抗蛋白水解消化的稳定性[1]
CHNQD-01522 (10-100 μM; 2 h) 可在 Huh-7 细胞中与 EBI 竞争 β-微管蛋白上的秋水仙碱结合位点[1]
CHNQD-01522 并非 P-gp 的底物,也不会调控 P-gp 的外排功能,表明其对 P-gp 介导的多药耐药具有固有抗性[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[1]

Cell Line: Huh-7
Concentration: 0.125 μM, 0.25 μM
Incubation Time: 24 h
Result: Increased the proportion of G2/M phase-arrested cells.
Reduced the proportion of G1 phase-arrested cells.

Apoptosis Analysis[1]

Cell Line: Huh-7
Concentration: 0.125 μM, 0.25 μM
Incubation Time: 24 h
Result: Raised the total apoptotic cell population from 2.51% (control) to 31.84% at 0.25 μM.

Western Blot Analysis[1]

Cell Line: Huh-7
Concentration: 0.125 μM, 0.25 μM, 0.5 μM
Incubation Time: 24 h
Result: Upregulated Bax expression in a dose-dependent manner.
Activated caspase-9 and caspase-3 in a dose-dependent manner.

Immunofluorescence[1]

Cell Line: Huh-7
Concentration: 0.125 μM, 0.25 μM
Incubation Time: 6 h
Result: Induced marked disruption of the microtubule cytoskeleton, with structural alterations similar to those caused by vincristine.
药代动力学
(Parmacokinetics)
Species Dose Route T1/2 Tmax Cmax AUC0-t MRT0-t F C0
Rat[1] 2.5 mg/kg i.v. 0.336 h 0.083 h 6140.244 ng/mL 3180.121 ng·h/mL 0.356 h 100 % 7515.850 ng/mL
Rat[1] 10 mg/kg i.p. 1.326 h 0.083 h 12122.205 ng/mL 11041.089 ng·h/mL 1.097 h 86.8 % /
Rat[1] 30 mg/kg p.o. 8.421 h 0.25 h 822.671 ng/mL 3325.864 ng·h/mL 14.011 h 8.715 % /
体内研究
(In Vivo)

CHNQD-01522 (Compound 18) (2 mg/kg;腹腔注射;每日一次/每日两次/每日三次;14 days) 在 Huh‑7 皮下异种移植模型中展现出显著的给药频率依赖性抗肝细胞癌活性,在 2 mg/kg,每日三次 给药方案下的肿瘤重量生长抑制率达 79.09%,且具有良好的安全性特征[1]
CHNQD-01522 (1 mg/kg;腹腔注射;每日三次;14 days) 在 Huh-7 原位肝细胞癌异种移植模型中可显著缩小肿瘤体积,且未观察到体重下降[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c-nu (female, 6-7 weeks old, 14 ± 1 g, Huh‑7 subcutaneous xenograft model)[1]
Dosage: 2 mg/kg
Administration: i.p.; QD/BID/TID; 14 days
Result: Achieved a tumor growth inhibition (TGI) rate of 70.22% for tumor volume and 79.09% for tumor weight with 2 mg/kg TID regimen.
Delayed tumor progression in a dosing frequency-dependent manner.
Caused no significant body weight changes or adverse effects in any treated groups.
Animal Model: BALB/c-nu (female, 6-7 weeks old, 14 ± 1 g, Huh‑7 orthotopic xenograft model)[1]
Dosage: 1 mg/kg
Administration: i.p.; TID; 14 days
Result: Resulted in a statistically significant reduction in tumor volume compared to the control group.
Caused no notable body weight changes in the treatment group.
分子量

354.36

Formula

C19H18N2O5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
CHNQD-01522
目录号:
HY-181675
需求量: